(Total Views: 901)
Posted On: 04/01/2018 12:15:29 PM
Post# of 30082
Happy Easter to All including those at Amarantus, JDRF and the team at the University of Helsinki. I hope your research is going well and diabetes can be the next after ophthalmology gets started this year for the company.
Additional funding for investigating the therapeutic role for neurotrophic factor MANF in type 1 diabetes
7-26-2017
The collaboration team has for the third time been awarded a research grant by the Juvenile Diabetes Research Foundation. The $ 495,000 grant is for two years. The Juvenile Diabetes Research Foundation is the leading global foundation funding type 1 diabetes research.
https://www.helsinki.fi/en/news/health/additi...1-diabetes
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
SAN FRANCISCO, Dec. 11, 2017
MANF Therapeutics is preparing to restart IND-enabling development of MANF in 2018, initially in ophthalmology. There is strong belief that MANF has significant therapeutic potential across multiple disease areas, including large indications such as diabetes and cardiovascular disease.
https://www.amarantus.com/news/press-releases...-notice-of
Additional funding for investigating the therapeutic role for neurotrophic factor MANF in type 1 diabetes
7-26-2017
The collaboration team has for the third time been awarded a research grant by the Juvenile Diabetes Research Foundation. The $ 495,000 grant is for two years. The Juvenile Diabetes Research Foundation is the leading global foundation funding type 1 diabetes research.
https://www.helsinki.fi/en/news/health/additi...1-diabetes
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
SAN FRANCISCO, Dec. 11, 2017
MANF Therapeutics is preparing to restart IND-enabling development of MANF in 2018, initially in ophthalmology. There is strong belief that MANF has significant therapeutic potential across multiple disease areas, including large indications such as diabetes and cardiovascular disease.
https://www.amarantus.com/news/press-releases...-notice-of
(9)
(0)
